Tinea Cruris

2 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Tinea Cruris has 2 FDA-approved novel treatments, led by JOURNEY. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Tinea Cruris Market Leaders

Companies with the most FDA-approved novel Tinea Cruris drugs.

Tinea Cruris Clinical Pipeline by Phase

8 industry-sponsored trials across 6 sponsors

Showing 3 of 3 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bausch Health Americas, Inc.	Luliconazole Cream 1%	—	COMPLETED	2016-04-27	NCT02767271
Bausch & Lomb Incorporated	Omeprazole 40 mg	—	COMPLETED	2015-04-01	NCT02394340
Merz North America, Inc.	NAFT500 (pediatric)	—	COMPLETED	2013-11	NCT01712360

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Merz North America, Inc.	Naftin 1% Cream	—	COMPLETED	2013-11	NCT01885156
Tinea Pharmaceuticals	Product 33525	—	COMPLETED	2012-09	NCT01349998
Medicis Global Service Corporation	33525	—	COMPLETED	2012-03	NCT01342315
Merz North America, Inc.	NAFT-500	—	COMPLETED	2009-08	NCT00750152

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Therapeutics, Inc.	UHE-103 Cream	—	COMPLETED	2023-11-14	NCT05363449

Novel Tinea Cruris Drugs by Company (New molecular entities)

2 companies have an FDA-approved novel drug for Tinea Cruris.

JOURNEY 1 drug

BAUSCH 1 drug

Reformulations (2 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Generic Drugs (7 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

CLOTRIMAZOLE

ENCUBE

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

GLENMARK SPECLT